Bharat Biotech said the price of the supply of covaxin to the center on ₹ 150 / dose, is a price that is not competitive and clearly unsustainable in the long run
Bharat Biotech, a manufacturer of Covid Covaxin vaccine, has said that the current price where the vaccine was supplied to an unsustainable central government. Therefore, higher prices in private markets are needed to compensate for some of the costs.
“The price of the supply of Covaxin to the Indian government at a price of ₹ 150 / dose, is a price that is not competitive and clearly unsustainable in the long run. Therefore a higher price in the private market is needed to compensate for part of the cost,” said company said.
Bharat Biotech has provided a vaccine to the center with a level of concession ₹ 150 per dose, while prices are higher for the state and private players. The company has saved 50% of its capacity provided for the launch of the free vaccine center.
In April, Bharat Biotech announced that the vaccine would cost ₹ 600 per dose to the state government and ₹ 1200 per dose to a private hospital. It is higher than the Serum Institute, Covishield manufacturer, another vaccine that must be approved in India, has announced a few days ago.
However, the days change, it cuts prices for the state to ₹ 400 per dose.
Covaxin has developed Bharat Biotech in collaboration with the ICMR National Virology Institute.
The company defends the current price for private hospitals and says that there is an instance directly from a pricing policy where the Papilloma human virus vaccine is valued for the supply of GAVI for $ 4.5 per dose (₹ 320), but also available on the private market at ₹ 3500 . Per dose.
“Rotavirus vaccines are supplied to the Indian government with ₹ 60 per dose, but also available on the private market with ₹ 1700 per dose. Prices for Covid-19 International Vaccines varies between $ 10 to $ 37 per dose, (₹ 730 – ₹ 2700 / dosage ), “said the company.